These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22017232)

  • 1. Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck.
    Levy AR; Johnston KM; Sambrook J; Donato B; Penrod JR; Corral M; Chasen M
    Curr Med Res Opin; 2011 Dec; 27(12):2253-9. PubMed ID: 22017232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
    Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies.
    Petrelli F; Coinu A; Riboldi V; Borgonovo K; Ghilardi M; Cabiddu M; Lonati V; Sarti E; Barni S
    Oral Oncol; 2014 Nov; 50(11):1041-8. PubMed ID: 25176576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
    Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
    Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.
    Heukelom J; Hamming O; Bartelink H; Hoebers F; Giralt J; Herlestam T; Verheij M; van den Brekel M; Vogel W; Slevin N; Deutsch E; Sonke JJ; Lambin P; Rasch C
    BMC Cancer; 2013 Feb; 13():84. PubMed ID: 23433435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis.
    Huang J; Zhang J; Shi C; Liu L; Wei Y
    BMC Cancer; 2016 Aug; 16(1):689. PubMed ID: 27565887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
    Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.
    Frampton JE
    Drugs; 2010 Oct; 70(15):1987-2010. PubMed ID: 20883055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck.
    Shetty AV; Wong DJ
    Otolaryngol Clin North Am; 2017 Aug; 50(4):775-782. PubMed ID: 28755705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
    Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study.
    Heron DE; Rwigema JC; Gibson MK; Burton SA; Quinn AE; Ferris RL
    Am J Clin Oncol; 2011 Apr; 34(2):165-72. PubMed ID: 20686406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer.
    Huang J; Baschnagel AM; Chen P; Gustafson G; Jaiyesmi I; Folbe M; Ye H; Akervall J; Krauss D
    Int J Clin Oncol; 2014 Apr; 19(2):240-6. PubMed ID: 23479120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results.
    Balermpas P; Keller C; Hambek M; Wagenblast J; Seitz O; Rödel C; Weiss C
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e377-83. PubMed ID: 22414284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.
    Okano S; Yoshino T; Fujii M; Onozawa Y; Kodaira T; Fujii H; Akimoto T; Ishikura S; Oguchi M; Zenda S; de Blas B; Tahara M; Beier F
    Jpn J Clin Oncol; 2013 May; 43(5):476-82. PubMed ID: 23479383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).
    Tao Y; Aupérin A; Sun X; Sire C; Martin L; Coutte A; Lafond C; Miroir J; Liem X; Rolland F; Even C; Nguyen F; Saada E; Maillard A; Colin-Batailhou N; Thariat J; Guigay J; Bourhis J
    Eur J Cancer; 2020 Dec; 141():21-29. PubMed ID: 33125944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost analysis of cetuximab (Erbitux) plus radiotherapy (ERT) versus concomitant cisplatin plus radiotherapy (CRT) within an NHS oncology unit (single institution): a pilot study.
    Caroline B; Sundus Y; Dawn D; Carol G; Susan M
    Br J Radiol; 2016 Dec; 89(1068):20160105. PubMed ID: 27734748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.
    Xiang M; Holsinger FC; Colevas AD; Chen MM; Le QT; Beadle BM
    Cancer; 2018 Dec; 124(23):4486-4494. PubMed ID: 30332498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
    Martins RG; Parvathaneni U; Bauman JE; Sharma AK; Raez LE; Papagikos MA; Yunus F; Kurland BF; Eaton KD; Liao JJ; Mendez E; Futran N; Wang DX; Chai X; Wallace SG; Austin M; Schmidt R; Hayes DN
    J Clin Oncol; 2013 Apr; 31(11):1415-21. PubMed ID: 23460709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
    Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B
    Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
    Fayette J; Bonnin N; Ferlay C; Lallemant B; Ramade A; Favrel V; Zrounba P; Chabaud S; Pommier P; Poupart M; Céruse P
    Anticancer Drugs; 2013 Jul; 24(6):623-9. PubMed ID: 23542750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.